


Digital Wellbeing

Contractome-AI



PRODUCT LAUNCH

PARTNERS: InoCardia (United Kingdom), University of Coventry (United Kingdom), Cresset Biomolecular Discovery (United Kingdom), UCB Biopharma (Belgium)



Our Heart Contractility Learning Engine....

Delivers Predictive Data To Your Desktop....

So You Can Make Safer Medicines

Intelligent Cardiac Safety Screening

Contractome-AI is a learning engine used by Pharma & Biotech Companies in early Drug Discovery to develop safer drugs. It is an intelligent, online, virtual screen for drug-induced cardiac contractility.

Developing pharmaceuticals that do not show heart toxicity is particularly difficult. This is due to the lack of predictive technologies suitable for early Drug Discovery stage use.

Contractome-AI's combination of novel assay and computational methods improves early detection of heart contractility issues, helping avoid expensive downstream problems.

Contractome-AI meets this need by linking a drug's key chemical and biological assay data to its effect in man, and making this available as a rapid, online, virtual screen. It is a learning engine – the more real-world assay data added, the more predictive it becomes.



THE FUTURE OF
EUROPE'S DIGITAL
INNOVATION

eitdigital.eu

[f](#) [o](#) [i](#) [n](#) [t](#) @EIT_Digital



EIT Digital is supported by the EIT, a body of the European Union

Competitive Advantages

- Compatible with Medicinal Chemistry stage use
- Learning Engine: Predictivity improves with use
- Draws from multiple virtual and real-world data sources
- Online user interface for ease of use
- Secure, online, end-to-end encrypted

Target Markets

- Pharmaceutical and Biotechnology Companies
- Safety Pharmacologists
- Drug Discovery Project Leaders
- Computational Chemists
- Europe, US, Japan, China and International Markets

Status/ Traction

- Prototype Completed & available for online customer demonstration – Contact Us
- Contractome-AI is being developed by InoCardia, Cresset BioMolecular, Coventry University and UCB BioPharma

Road Map

2020

- MVP completion as a stand-alone online virtual screening platform

2021

- Launch of integrated screening platform as an InoCardia Cardiovascular Safety Service

Leveraged Technologies

PoC: development of a cellular system to predict cardiac contractility risk in Man. PoC: demonstration that this can be used to rank structurally related ligands, transfer to an AI platform and show ability to predict previously unknown structural features governing contractility risk.

Contact



Dr Jeremy Billson
Business Champion & Activity Leader

e: jeremy.billson@inocardia.com
t: +44 (0) 7988 563489

InoCardia | The TechnoCentre | Puma Way
Coventry | CV1 2TT | United Kingdom



Contractome-AI is an innovation activity proudly supported by EIT Digital.

EIT Digital supports entrepreneurial teams from research and business organisations in launching new startups and new products in agile 12-month projects called innovation activities. These activities are embedded in EIT Digital's European ecosystem and receive a financial co-investment to package their technology, sign up customers and attract investors.